Claims
- 1. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:6.
- 2. An anti-1L4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
- 3. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:6 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
- 4. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:10.
- 5. An anti-1L4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
- 6. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:10 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
- 7. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:14.
- 8. An anti-1L4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 16.
- 9. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:14 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 16.
- 10. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 18.
- 11. An anti-1L4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 20.
- 12. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 18 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 20.
- 13. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 22.
- 14. An anti-1L4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 24.
- 15. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:22 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 24.
- 16. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 26.
- 17. An anti-1L4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:26 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 24.
- 18. A method for treating septic arthritis, comprising administering an IL-4 antagonist to a mammal afflicted with septic arthritis.
- 19. A method of claim 1, wherein said antagonist is a soluble form of the human IL-4 receptor (IL-4R) of SEQ ID NO:2, and the mammal is a human.
- 20. A method of claim 1, wherein said antagonist is an antibody that inhibits the binding of IL-4 to an IL-4R.
- 21. A method of claim 1, wherein said antagonist is administered in the form of a composition that additionally comprises a diluent, excipient, or carrier.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of application Ser. No. 09/847,816, filed May 1, 2001, currently pending, which is a continuation-in-part of application Ser. No. 09/785,934, filed Feb. 15, 2001, currently pending, which is a continuation-in-part of application Ser. No. 09/665,343, filed Sep. 19, 2000, abandoned, which is a continuation-in-part of application Ser. No. 09/579,808, filed May 26, 2000, abandoned.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09847816 |
May 2001 |
US |
Child |
10324493 |
Dec 2002 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
09785934 |
Feb 2001 |
US |
Child |
09847816 |
May 2001 |
US |
Parent |
09665343 |
Sep 2000 |
US |
Child |
09785934 |
Feb 2001 |
US |
Parent |
09579808 |
May 2000 |
US |
Child |
09665343 |
Sep 2000 |
US |